Market Capitalization

Korean brand Laka brings its gender-neutral philosophy to Sephora, betting that US consumers are ready for beauty without rigid rules or boundaries.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

The chemical giant's dramatic dividend cut ends a 14-year growth streak, raising questions about sector health and long-term investor returns.

Seagate retires $600M in debt for cash and stock. A strategic move to fortify its balance sheet, but what does the share dilution mean for investors?

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Facing delisting, the Singaporean tech firm enacts a 1-for-20 reverse split. Is it a lifeline or a sign of deeper financial troubles ahead?

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

As it heads to key conferences, Orchestra BioMed is pitching its novel pacemaker-based hypertension treatment and a unique drug-eluting balloon.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

After a volatile market debut, the supersonic flight company hits the NYSE, signaling a new era for high-speed testing and air-launch services.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

At a major scientific conference, Seer Inc.'s Proteograph platform is taking center stage, promising deeper insights into Alzheimer's and heart disease.

Specialist asset manager Sprott Inc. leverages a volatile market and geopolitical tensions, riding a precious metals boom to record profits and AUM growth.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

With a high-yield but unstable dividend, Brandywine's Q1 earnings will reveal its strategy for navigating the challenging urban office market.

Carmila's 2025 results reveal a powerful strategy of innovation and acquisition, driving record profits and hinting at a broader market recovery.

The hydration expert launches a new line of functional drink mixes for cravings, immunity, and energy, tapping into the booming wellness market.

Lucerne Capital Management appoints veteran Frank Austin to head its new U.S. farmland strategy, signaling a deeper Wall Street move into agriculture.

Over 100 institutions, including BlackRock and Vanguard, now hold Chaince Digital. What's driving this quiet endorsement of a firm pivoting to AI and tokenization?

Creative Realities repurchased 1.7M stock warrants for just $200,000, a strategic move to prevent dilution and pave the way for ambitious growth.